Quick Answer
CNS Pharmaceuticals, Inc. reported Net Income of -$15.85 million for fiscal year 2025.
CNS Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$15.85M | -6.7% |
| 2024 | -$14.86M | +21.2% |
| 2023 | -$18.85M | -23.4% |
| 2022 | -$15.27M | -5.4% |
| 2021 | -$14.50M | -53.3% |
| 2020 | -$9.46M | -143.9% |
| 2019 | -$3.88M | +47.5% |
| 2018 | -$7.39M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.22M | +42.6% | -35.5% |
| June 30, 2025 | -$2.37M | +6.2% | +44.8% |
| March 31, 2025 | -$4.30M | -21.3% | +23.3% |
| September 30, 2024 | -$5.61M | -23.9% | -121.5% |
| June 30, 2024 | -$2.53M | +37.1% | +28.6% |
| March 31, 2024 | -$3.54M | +28.1% | +21.6% |
| September 30, 2023 | -$4.52M | -32.3% | -12.5% |
| June 30, 2023 | -$4.02M | -12.8% | +18.5% |
- CNS Pharmaceuticals, Inc. showed a decrease of -6.7% in Net Income compared to the prior fiscal year.
- Over the 2018–2025 period, CNS Pharmaceuticals, Inc.’s net income has declined by 114.4% (from -$7.39 million to -$15.85 million).
- The most recent figure is from CNS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: